Publications
Stewart O, Gruber C, Randolph HE, Patel R, Ramba M, Calzoni E, Huang LH, Levy J, Buta S, Lee A, Sazeides C, Prue Z, Hoytema van Konijnenburg DP, Chinn IK, Pedroza LA, Lupski JR, Schmitt EG, Cooper MA, Puel A, Peng X, Boisson-Dupuis S, Bustamante J, Okada S, Martin-Fernandez M, Orange JS, Casanova JL, Milner JD, Bogunovic D. Monoallelic expression can govern penetrance of inborn errors of immunity. Nature. 2025. PMID: 39743591
Ng DL, Van Loon K, Weidler J, Bates M, Mmbaga EJ, Vuhahula E. FNAB samples with the STRAT4 assay for breast cancer diagnosis - Authors' reply. The Lancet. Oncology. 2025. PMID: 39756449
Trapani D, Jin Q, Miller KD, Rugo HS, Reeder-Hayes KE, Traina T, Abdou Y, Falkson C, Abramson V, Ligibel J, Chen W, Come S, Nohria A, Ryabin N, Tayob N, Tolaney SM, Burstein HJ, Mayer EL. Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials. Clinical breast cancer. 2024. PMID: 39890560
Banerjee S, Le P, Yang H, Zhang L, He T. TCR-NP: a novel approach to prioritize T-cell Receptor repertoire network properties. Statistics Innovation. 2024. PMID: 40052086
Banerjee S, Le P, Yang H, Zhang L and He T. TCR-NP: a novel approach to prioritize T-cell receptor repertoire network properties Statistics Innovation. 2024. PMID:
Amaria RN, Komanduri KV, Schoenfeld AJ, Ramsingh G, Burga RA, Jagasia MH. Entering a new era of tumor-infiltrating lymphocyte cell therapy innovation. Cytotherapy. 2024. PMID: 40131263
Gaballa MR, Castaneda Puglianini O, Cohen AD, Vogl DT, Chung A, Ferreri CJ, Voorhees PM, Hansen DK, Patel KK. BCMA-directed CAR T-cell Therapy in patients with multiple myeloma and CNS involvement. Blood advances. 2024. PMID: 39729503
Xu MJ, Haddadi S, Mushi BP, Zhang L, Sama G, Nyagabona SK, Ng D, Muya S, Malango AE, Richard E, Ha P, Yom SS, Massawe W, Mmbaga EJ, Van Loon K, Nkya A. Treatment initiation and completion among head and neck squamous cell carcinoma patients in Tanzania. BMC research notes. 2024. PMID: 39716326
Xu MJ, Haddadi S, Mushi BP, Zhang L, Sama G, Nyagabona SK, Ng D, Muya S, Malango AE, Richard E, Ha P, Yom SS, Massawe W, Mmbaga EJ, Van Loon K, Nkya A. Treatment initiation and completion among head and neck squamous cell carcinoma patients in Tanzania. BMC research notes. 2024. PMID: 39716326
Thiruvengadam SK, Merryman R, Wang Y, Gaulin C, Bezerra E, Voorhees T, Seshadri MR, Falade A, Habib A, Ayers AA, Bailey M, Brown A, Bailey N, Patel K, Andreadis CB, Kittai AS, Jacobson C, Palmer J, Forman SJ, Nastoupil L, Budde LE. Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma. American journal of hematology. 2024. PMID: 39715004
Ko AH, Oh DY, Lau J, Mhatre SK, Ci B, Machado R, Li S, Bretscher MT, Reyes-Rivera I, Zhu J, Zhang X, Patel J, Psioda MA, Ponz-Sarvise M. Investigational Use of Real-World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma from the Randomized Phase Ib/II MORPHEUS Trial. Volume 117 of Issue 4 Clinical pharmacology and therapeutics. 2024. PMID: 39707623
Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, Bakaloudi D, Davidsohn M, Freeman D, Glover M, Khaki AR, Evans S, Lemke E, Bose R, Sim W, Pywell C, Basu A, Kilari D, Barata PC, Bilen MA, Zakharia Y, Milowsky MI, Shah SA, Bellmunt J, Grivas P, Emamekhoo H, Davis NB, Gupta S, Hoimes C, Campbell MT, Alva A, Koshkin VS. Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data. European urology oncology. 2024. PMID: 39709257
Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, Bakaloudi D, Davidsohn M, Freeman D, Glover M, Khaki AR, Evans S, Lemke E, Bose R, Sim W, Pywell C, Basu A, Kilari D, Barata PC, Bilen MA, Zakharia Y, Milowsky MI, Shah SA, Bellmunt J, Grivas P, Emamekhoo H, Davis NB, Gupta S, Hoimes C, Campbell MT, Alva A, Koshkin VS. Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data. European urology oncology. 2024. PMID: 39709257
Koshkin VS, Danchaivijitr P, Bae WK, Semenov A, Ozyilkan O, Su YL, Arranz Arija JA, Tsujihata M, Bögemann M, Hendriks MP, Delgado SN, Rosenbaum E, Lopez KA, Bavle A, Liu CC, Imai K, Furka A. Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy. European urology. 2024. PMID: 39709248
Goyal L, DiToro D, Facchinetti F, Martin EE, Peng P, Baiev I, Iyer R, Maurer J, Reyes S, Zhang K, Majeed U, Berchuck JE, Chen CT, Walmsley C, Pinto C, Vasseur D, Gordan JD, Mody K, Borad M, Karasic T, Damjanov N, Danysh BP, Wehrenberg-Klee E, Kambadakone AR, Saha SK, Hoffman ID, Nelson KJ, Iyer S, Qiang X, Sun C, Wang H, Li L, Javle M, Lin B, Harris W, Zhu AX, Cleary JM, Flaherty KT, Harris T, Shroff RT, Leshchiner I, Parida L, Kelley RK, Fan J, Stone JR, Uboha NV, Hirai H, Sootome H, Wu F, Bensen DC, Hollebecque A, Friboulet L, Lennerz JK, Getz G, Juric D. A Model for Decoding Resistance in Precision Oncology: Acquired Resistance to FGFR inhibitors in Cholangiocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2024. PMID: 39706336
Lingappa AF, Akintunde O, Samueli E, Ewald C, Michon M, Ziari N, Lu M, Yu SF, Froehlich M, Le PU, Fernandez Y, Mallesh S, Lin J, Kitaygorodskyy A, Solas D, Reed JC, Lingappa JR, Müller-Schiffmann A, Korth C, Prasad D, Nalca A, Aston E, Fabbri B, Anand SK, Campi TW, Petrouski E, Dey D, Andrews DW, Rubenstein JL, Lingappa VR. Small molecule protein assembly modulators with pan-cancer therapeutic efficacy. Open biology. 2024. PMID: 39689856
Kui K, Hailozian C, Thai M, Chakravarty D, Apollonio DE, Kroon L, Vijayaraghavan M. Tobacco cessation, mental health, and substance use in a community pharmacist-linked cessation program for people experiencing homelessness. Drug and alcohol dependence. 2024. PMID: 39729805
Oliai C, Park S, Damon LE, Jonas BA, Jeyakumar D, Wieduwilt MJ, Logan AC, Callas B, Hannigan CA, Gaut DL, Schiller GJ. CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial. Leukemia & lymphoma. 2024. PMID: 39689718
Oliai C, Park S, Damon LE, Jonas BA, Jeyakumar D, Wieduwilt MJ, Logan AC, Callas B, Hannigan CA, Gaut DL, Schiller GJ. CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial. Leukemia & lymphoma. 2024. PMID: 39689718
Oliai C, Park S, Damon LE, Jonas BA, Jeyakumar D, Wieduwilt MJ, Logan AC, Callas B, Hannigan CA, Gaut DL, Schiller GJ. CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial. Leukemia & lymphoma. 2024. PMID: 39689718